Creative Life Science Co Rule of 40
The Rule of 40 of Creative Life Science Co (7837.TWO) as of Oct 15, 2026 is 38.34 %. In the previous year, Rule of 40 was -6.77 % — a change of -666.00% (higher).
Get this data via API
Financial Data API
Rule of 40
38.34 %
YoY
-666.00%
Last updated:
Rule of 40 of Creative Life Science Co is 2024 38.34 % . Rule of 40 of Creative Life Science Co was 2023 -6.77 % . It decreases by -666.00% higher compared to the previous year.
The Creative Life Science Co Rule of 40 history
3 Years
10 Years
25 Years
Max
Rule of 40
Date
Rule of 40
Jan 1, 2023
-6.77 TWD
Jan 1, 2024
38.34 TWD
| YEAR | Rule of 40 | YoY |
|---|---|---|
| 38.34 % | -666.00% | |
| -6.77 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Creative Life Science Co Stock analysis
What does Creative Life Science Co do? Creative Life Science Co Ltd is a company based in Taipei, Taiwan, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company went public on May 28, 2025, with the ticker 7837.TWO and ISIN TW0007837007. Creative Life Science develops and manufactures microbiological products, including its own brand, CMP, and acts as an agent for international brands. The CMP product range encompasses storage and carrying culture media, sterile transport containers, buffers and diluents, identification reagents, various culture media types, and selective culture media. The company also distributes dry powder culture media, detection reagents, in vitro diagnostic (IVD) culture media, sampling and transportation systems, and related products. Its offerings serve multiple sectors including pharmaceuticals, biotechnology, food, medical diagnosis, environmental monitoring, and academic research. The company provides testing, inspection, and certification services. Creative Life Science primarily focuses on the Taiwanese market for product distribution. The company's website is https://www.cmp-micro.com/. Creative Life Science Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Creative Life Science Co stock
Rule of 40 of Creative Life Science Co is 38.34 % in 2024.
On Eulerpool you can find the complete historical development of Rule of 40 Creative Life Science Co since 2006 – with annual values, charts, and detailed analysis.
The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Creative Life Science Co
All Key Metrics — Creative Life Science Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth